<DOC>
	<DOCNO>NCT01930773</DOCNO>
	<brief_summary>Patients undergo percutaneous coronary intervention residual high platelet reactivity despite oral clopidogrel increase risk ischaemic complication . The strategy overcome issue consist switch potent antiplatelet medication include prasugrel ticagrelor . Economic constrain many country still allow wide reimbursement new antiplatelet agent . Therefore strategy personalise treatment accord genotype phenotype characteristic patient may provide attractive solution combine high clinical efficacy low budget impact .</brief_summary>
	<brief_title>Bedside Genetic Pharmacodynamic Testing Prevent Periprocedural Myonecrosis During PCI ( ONSIDE TEST )</brief_title>
	<detailed_description />
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>age 1875 elective PCI acute coronary syndrome ( troponin &gt; 1 x ULN ) , administration glycoprotein IIb/IIIa inhibitor , chronic total occlusion , lesion extensive calcification require rotational atherectomy , platelet count &lt; 70 000 /Âµl high bleeding risk , coronary bypass surgery previous 3 month , severe chronic renal failure ( eGFR &lt; 30 mL/min ) requirement warfarin , dabigatran , apixaban , rivaroxaban history stroke TIA , weight &lt; 60 kg know bleed diathesis , hematocrit &lt; 30 % &gt; 52 % pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>clopidogrel</keyword>
	<keyword>prasugrel</keyword>
	<keyword>platelet function test</keyword>
	<keyword>genotyping</keyword>
	<keyword>peri-procedural MI</keyword>
</DOC>